Meeder Asset Management Inc Solid Biosciences Inc. Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$0.43 - $1.24 $2,595 - $7,484	-6,036 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$0.74 - $1.79 $4,466 - $10,804	6,036 New	6,036 $7,000
Q3 2021 Nov 08, 2021	SELL	$2.38 - $3.77 $159 - $252	-67 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$3.49 - $5.51 $16,668 - $26,315	-4,776 Reduced 98.62%	67 $0
Q1 2021 Apr 28, 2021	BUY	$5.37 - $10.72 $26,006 - $51,916	4,843 New	4,843 $27,000
Q2 2020 Aug 11, 2020	SELL	$2.1 - $3.42 $1,644 - $2,677	-783 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.31 - $4.43 $1,808 - $3,468	783 New	783 $2,000
Q1 2019 Apr 16, 2019	SELL	$7.19 - $32.37 $93 - $420	-13 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$21.32 - $46.34 $277 - $602	13 New	13 $0
Q3 2018 Nov 02, 2018	SELL	$36.35 - $51.7 $2,508 - $3,567	-69 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$7.33 - $43.15 $505 - $2,977	69 New	69 $0

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.